Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination

Fig. 1

Treatment outcomes and anti-hTERT immune response induction in patients treated with UV1 and ipilimumab. A Progression-free survival and B overall survival in all patients enrolled (n = 12). C Maximum change in the sum of longest diameter in RECIST 1.1 evaluable patients (n = 9). D Duration of response (n = 4). E Maximum T cell proliferation response in terms of stimulation index (SI) in evaluable patients (n = 11). The dotted line represents positivity threshold (SI ≥ 3). CR complete response, PR partial response, SD stable disease, PD progressive disease, IR immune response

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us